Tag Archives: GILD

Gilead Says Spinoff Of HCV Business Is “Not High On List Of Priorities”

By |
1 Comment

There was much investor chatter last month that Gilead Sciences(GILD) could unlock value by splitting its Hepatitis C business from its HIV business.  RBC Capital advanced the case in a note RBC Capital suggested the drugmaker would be better off cutting its businesses right down the middle, saying that shares could jump by as much as 40% if… Read More »

Glaxo Has No Current Plans To Spin Off Viiv, But Does Not Rule It Out

By |
0 Comment

Whenever a corporate executive has to publicly state that they will not be spinning something off, it’s generally only a matter of time.  This is likely the case with GlaxoSmithKline(GSK) and its majority-owned Viiv Healthcare unit.  Viiv, of which Glaxo owns 76.5%, recently filed for approval for its anti-HIV drug, dolutegravir. If the drug is approved, it is… Read More »